HK:3320 China Resources Pharmaceutical Group Limited

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, distribution, and retail of pharmaceutical and healthcare products in the People's Republic of China and Hong Kong. The company operates through Manufacturing, Distribution, Retail, and Others segments. It offers chemical drugs, Chinese medicines formula granules, and biopharmaceutical drugs, as well as nutritional and healthcare products for a range of therapeutic areas, including cardiovascular, alimentary tract and metabolism, large-volume IV infusion, pediatrics, respiratory system, anti-infection, reproductive health, cold and cough, and dermatology. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in the manufacture and sale of medical equipment; and property holding activities. As of December 31, 2017, the company operated a network of approximately 786 retail pharmacies under the CR Care, Yibaoquanxin, Li'an chain, and Tung Tak Tong brand names. It offers its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. China Resources Pharmaceutical Group Limited was founded in 2007 and is headquartered in Wanchai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.

4.87 HKD
As of 06/18/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  China
Country of incorporation:  Hong Kong
IPO date:  10/28/2016
Stock exchange:    Hong Kong Exchange
Exchange country:   Hong Kong
Market cap:   31,475,376,128 HKD
Current dividend yield:   2.29%
CUSIP:    Y1511B108
ISIN:        HK0000311099
Sedol:      BYNGG26

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy